Compounded semaglutide and tirzepatide aren’t FDA-approved, and the FDA doesn’t check their safety, effectiveness or quality before they reach you. Some are made carefully; some aren’t, and from the outside you can’t tell which you have. If you’re on one, you should be able to name the pharmacy that made it and see proof of what’s in your batch. That’s why this practice prescribes brand-name, FDA-approved GLP-1s only.
Compounding isn’t bad. Mass-produced copies are the problem.
Pharmacists have compounded medicines for as long as there has been pharmacy, for real reasons: a national shortage, an allergy to an inactive ingredient, or a need no commercial product meets. That’s compounding doing its job.
What’s different with GLP-1s is scale. Copies of drugs you can already buy are being made in bulk and marketed widely, sometimes with added ingredients. The FDA has said the shortages of semaglutide and tirzepatide are over, which ended the main reason compounders were allowed to copy them.
What can go wrong
- The wrong ingredient. Some compounded semaglutide has used salt forms (semaglutide sodium or acetate) that aren’t the ingredient in Ozempic or Wegovy. Those may not behave the same way in the body.
- The wrong dose. The FDA has reported dosing errors with compounded GLP-1s, including people getting several times the intended dose, from varying concentrations, multi-dose vials and syringe confusion. Brand-name pens are built to prevent this.
- Counterfeits. The FDA warns that unapproved and counterfeit products can contain the wrong ingredient, or too much, too little or none of the active one.
Three questions to ask about yours
- Who is the pharmacy? Not the website you ordered from: the pharmacy. Its name should be on your label.
- Do they do third-party testing?
- Can you get the certificate of analysis for your batch? Not a sample: yours.
A reputable compounding pharmacy answers all three without hesitating. Even then, a certificate of analysis isn’t the same thing as FDA review, which covers clinical testing, manufacturing oversight and ongoing safety monitoring.
503A vs. 503B pharmacies
Not all compounding pharmacies are regulated the same way. 503A pharmacies are traditional compounders, overseen mainly by state boards and exempt from many federal manufacturing standards. 503B outsourcing facilities register with the FDA and must meet stricter manufacturing and quality rules. For an injectable medicine, that difference matters.
Why brand-name only here
With a brand-name pen you know exactly what’s in it and exactly what dose you took, and that’s the basis for adjusting your dose safely. If cost is what’s pushing you toward a compounded version, the makers now sell brand-name GLP-1s directly to self-pay patients; see current self-pay prices.
Sources
- FDA, concerns with unapproved GLP-1 drugs used for weight loss: no FDA review of compounded products, salt forms, dosing errors and counterfeits
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize: the semaglutide and tirzepatide shortages resolved
- FDA, Human Drug Compounding: the difference between 503A pharmacies and 503B outsourcing facilities
6 quick questions · about a minute · no email needed